LINKÖPING, Sweden--(BUSINESS WIRE)--Visceral fat, also known as Visceral Adipose Tissue (VAT), is the adipose tissue inside the abdominal cavity. VAT is a central risk factor for Non-Alcoholic Fatty Liver Disease (NAFLD), liver cirrhosis, cardiovascular disease (CVD), and type-2 diabetes (T2D). This study validates, prospectively, the precision and repeatability of AMRA Medical’s VAT biomarker for use in clinical trials..

瑞典LINKÖPING-（BUSINESS WIRE）-内脏脂肪，也称为内脏脂肪组织（VAT），是腹腔内的脂肪组织。增值税是非酒精性脂肪性肝病（NAFLD），肝硬化，心血管疾病（CVD）和2型糖尿病（T2D）的中心风险因素。这项研究前瞻性地验证了AMRA Medical增值税生物标志物在临床试验中的准确性和可重复性。。

Approximately 25% of the general population has NAFLD and a subset is affected by the more advanced form NASH (nonalcoholic steatohepatitis). Patients with NASH are at risk of liver-related and cardiovascular morbidity. There is an unmet need to identify those patients at risk and to facilitate clinical trials using non-invasive methods..

大约25%的普通人群患有NAFLD，一部分患者受到更高级的NASH（非酒精性脂肪性肝炎）的影响。NASH患者有肝脏相关和心血管疾病的风险。尚未满足的需求是识别那些有风险的患者并促进使用非侵入性方法的临床试验。。

The FNIH´s (Foundation for the National Institutes of Health) NIMBLE consortium (Non-invasive Biomarkers of Metabolic Liver Disease) is a collaborative research effort that aims to standardize, compare, and validate biomarkers for the non-invasive diagnosis and monitoring of NAFLD and NASH. NIMBLE partners with major pharmaceutical companies, academic centers, and key opinion leaders in industry, to evaluate candidate biomarkers for their suitability for wider implementation in clinical trials.

FNIH（美国国立卫生研究院基金会）NIMBLE联盟（代谢性肝病的非侵入性生物标志物）是一项合作研究工作，旨在标准化，比较和验证生物标志物，用于非侵入性诊断和监测NAFLD和NASH。NIMBLE与主要制药公司，学术中心和行业主要意见领袖合作，评估候选生物标志物是否适合在临床试验中广泛实施。

AMRA Medical´s VAT biomarker was chosen as one of the primary biomarkers in the NIMBLE 1.2 study, showing excellent repeatability in patients with NAFLD..

AMRA Medical的增值税生物标志物被选为NIMBLE 1.2研究中的主要生物标志物之一，在NAFLD患者中表现出优异的重复性。。

The NIMBLE 1.2 study was designed to assess the potential of using MRI-based biomarkers longitudinally in NAFLD/NASH clinical trials. In this first paper, published by Fowler et al. in Radiology, the repeatability of liver fat, liver stiffness, and VAT was assessed in patients with NAFLD. AMRA’s VAT biomarker was assessed as the primary body composition biomarker, due to the connection between obesity, CVD, insulin resistance, and NAFLD.

NIMBLE 1.2研究旨在评估在NAFLD/NASH临床试验中纵向使用基于MRI的生物标志物的潜力。在Fowler等人在放射学中发表的第一篇论文中，评估了NAFLD患者肝脏脂肪，肝脏硬度和增值税的可重复性。由于肥胖，心血管疾病，胰岛素抵抗和NAFLD之间的联系，AMRA的增值税生物标志物被评估为主要的身体成分生物标志物。

Data on other body composition biomarkers and metrics from AMRA have also been collected and will be reported in a future paper..

还收集了来自AMRA的其他身体成分生物标志物和指标的数据，并将在未来的论文中报告。。

This study found that AMRA’s VAT biomarker was reproducible across vendors (common MRI scanner manufacturers), field strengths, and temporal assessments, which supports the use of this biomarker in large-scale clinical trials.

这项研究发现，AMRA的增值税生物标志物在供应商（普通MRI扫描仪制造商），现场优势和时间评估方面具有可重复性，支持在大规模临床试验中使用该生物标志物。

Learn more about AMRA Medical’s MRI-based services via our website or connect with our team of experts for a detailed discussion at info@amramedical.com.

通过我们的网站了解有关AMRA Medical基于MRI的服务的更多信息，或与我们的专家团队联系以进行详细讨论info@amramedical.com.

About AMRA Medical

关于阿姆拉医疗

AMRA Medical is a health informatics company at the forefront of medical imaging and precision medicine. The company has developed a new global standard in body composition analysis, delivering multiple fat and muscle biomarkers with unrivaled accuracy and precision – all from a rapid whole-body MRI scan.

AMRA Medical是一家位于医学成像和精准医学前沿的健康信息公司。该公司已经开发出一种新的全球身体成分分析标准，提供多种脂肪和肌肉生物标志物，具有无与伦比的准确性和精确度-所有这些都来自快速的全身MRI扫描。

AMRA offers clinical services and research services to support transformative care and vital decision-making, from clinical research to clinical care..

AMRA提供临床服务和研究服务，以支持从临床研究到临床护理的变革性护理和重要决策。。

Follow AMRA on LinkedIn for the latest updates in body composition and precision medicine.

按照LinkedIn上的AMRA了解身体成分和精准医学的最新更新。